The ASCO-SNO-ASTRO guidelines recommend alectinib, brigatinib, and ceritinib for ALK-positive NSCLC cases with asymptomatic brain metastases and state that local therapy can be postponed until intracranial progression when administered with these drugs. Here, ALK is linked to non-small cell lung carcinoma.